AstraZeneca’s Nexium, GSK’s Zofran Among Latest Victims Of China Price Cuts; NDRC Plans Further Pricing Reforms To Encourage Innovation
This article was originally published in PharmAsia News
Executive Summary
China has announced another round of price cuts, this time targeting digestive drugs, which will impact AstraZeneca, GlaxoSmithKline and other MNCs.